|
|
Last Modified: 6/9/2008  First Published: 10/26/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Temporarily closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
DFCI-07070 07-070, 7881, NCT00551421
|
|
|
|
|
|
|
|
Last Modified: 7/2/2004  First Published: 7/26/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
MSKCC-03048 GENENTECH-TOC2682g, NCT00066755
|
|
|
|
|
|
|
|
Last Modified: 2/12/2004  First Published: 9/24/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
UCLA-0303080 GENENTECH-TOC2689g, NCT00070408
|
|
|
|
|
|
|
|
Last Modified: 12/2/2004  First Published: 10/25/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
UCLA-0405066-01 GENENTECH-TOC2572g, NCT00063154
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Not specified
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
TOC2664g NCT00096941
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
TOC3258g NCT00096993
|
|
|
|
|
|
|
|
Last Modified: 10/10/2008  First Published: 3/3/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCI-06-C-0035 NCI-P6660, NCT00301899
|
|
|
|